Catalyst Net Income Applicable To Common Shares from 2010 to 2026
| CPRX Stock | USD 23.91 1.15 4.59% |
Net Income Applicable To Common Shares | First Reported 2004-12-31 | Previous Quarter 29.6 M | Current Value 37.8 M | Quarterly Volatility 10.1 M |
Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 358.2 M or Operating Income of 235.6 M, as well as many indicators such as Price To Sales Ratio of 5.49, Dividend Yield of 0.0 or PTB Ratio of 3.71. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
Catalyst | Net Income Applicable To Common Shares | Build AI portfolio with Catalyst Stock |
The evolution of Net Income Applicable To Common Shares for Catalyst Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Catalyst Pharmaceuticals compares to historical norms and industry peers.
Latest Catalyst Pharmaceuticals' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Catalyst Pharmaceuticals over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Catalyst Pharmaceuticals' Net Income Applicable To Common Shares historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Catalyst Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | 26,834,860 | |
| Coefficient Of Variation | 182.97 | |
| Mean Deviation | 44,324,377 | |
| Median | (4,076,386) | |
| Standard Deviation | 49,098,981 | |
| Sample Variance | 2410.7T | |
| Range | 134.3M | |
| R-Value | 0.85 | |
| Mean Square Error | 708.9T | |
| R-Squared | 0.72 | |
| Significance | 0.000015 | |
| Slope | 8,274,978 | |
| Total Sum of Squares | 38571.4T |
Catalyst Net Income Applicable To Common Shares History
About Catalyst Pharmaceuticals Financial Statements
Catalyst Pharmaceuticals investors use historical fundamental indicators, such as Catalyst Pharmaceuticals' Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 95.5 M | 100.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.